NASDAQ:SMMT Summit Therapeutics (SMMT) Stock Price, News & Analysis → Central Bank Gold Heist In Progress (From Colonial Metals) (Ad) Free SMMT Stock Alerts $4.12 -0.50 (-10.83%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$4.10▼$4.5650-Day Range$2.97▼$5.0752-Week Range$1.30▼$5.22Volume2.28 million shsAverage Volume2.26 million shsMarket Capitalization$2.89 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Summit Therapeutics alerts: Email Address Ad Banyan Hill PublishingAI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… ]click here to watch a free presentation where I reveal all the details of this lucrative opportunit About Summit Therapeutics Stock (NASDAQ:SMMT)Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.Read More SMMT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SMMT Stock News HeadlinesMarch 14, 2024 | businesswire.comIntracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024March 11, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMTMarch 18, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… March 5, 2024 | businesswire.comSummit Therapeutics to Present at the Barclays 26th Annual Global Healthcare ConferenceMarch 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMTFebruary 27, 2024 | msn.comSHAREHOLDER ALERT: Potential Recovery for Summit Therapeutics Inc. (SMMT) InvestorsFebruary 26, 2024 | businesswire.comSummit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsFebruary 21, 2024 | uk.finance.yahoo.comSummit Therapeutics plc (SMMT)March 18, 2024 | Monument Traders Alliance (Ad)Make This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…February 21, 2024 | finance.yahoo.comQ4 2023 Summit Therapeutics Inc Earnings CallFebruary 21, 2024 | finance.yahoo.comSummit Therapeutics Inc. (NASDAQ:SMMT) Q4 2023 Earnings Call TranscriptFebruary 20, 2024 | finance.yahoo.comSummit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023February 20, 2024 | finance.yahoo.comSummit Therapeutics Inc (SMMT) Reports Comprehensive 2023 Financial Results and Clinical ...February 20, 2024 | businesswire.comSummit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023February 17, 2024 | finance.yahoo.comSMMT Mar 2024 4.000 putFebruary 17, 2024 | finance.yahoo.comSMMT Apr 2024 3.000 callFebruary 14, 2024 | businesswire.comSummit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024February 14, 2024 | finance.yahoo.comSummit Therapeutics to Host Fourth Quarter & Full Year 2023February 14, 2024 | businesswire.comSummit Therapeutics to Host Fourth Quarter & Full Year 2023January 30, 2024 | seekingalpha.comSummit Therapeutics: A Strategic Analysis Of Ivonescimab's ProgressJanuary 8, 2024 | finance.yahoo.comSummit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare ConferenceJanuary 3, 2024 | finance.yahoo.comSummit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNovember 7, 2023 | finance.yahoo.comSummit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023November 7, 2023 | finance.yahoo.comSummit Therapeutics Inc (SMMT) Reports Q3 Financial Results and Operational ProgressNovember 2, 2023 | finance.yahoo.comIvonescimab's Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023November 1, 2023 | bizjournals.comFormer Reata Pharmaceuticals CFO steps into new role with California biotech companyOctober 31, 2023 | finance.yahoo.comIvonescimab’s Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023See More Headlines Receive SMMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/20/2024Today3/18/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SMMT CUSIPN/A CIK1599298 Webwww.summitplc.com Phone650-460-8308Fax44-12-3544-3999Employees105Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-614,930,000.00 Net MarginsN/A Pretax Margin-271,685.00% Return on Equity-87.45% Return on Assets-41.17% Debt Debt-to-Equity Ratio1.29 Current Ratio9.30 Quick Ratio9.30 Sales & Book Value Annual Sales$700,000.00 Price / Sales4,124.99 Cash FlowN/A Price / Cash FlowN/A Book Value$0.11 per share Price / Book37.41Miscellaneous Outstanding Shares701,700,000Free Float114,378,000Market Cap$2.89 billion OptionableOptionable Beta-1.21 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Robert W. Duggan (Age 79)Co-CEO & Executive Chairman Dr. Mahkam Zanganeh D.D.S. (Age 54)M.B.A., Co-CEO, President & Director Comp: $657.81kMr. Ankur Dhingra (Age 47)Chief Financial Officer Comp: $530kMr. Manmeet Singh Soni (Age 46)COO & Director Comp: $591.5kProf. Dame Kay Davies DBE (Age 73)FRS CBE, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor Ms. Abby Guzman MurphyHead of Human ResourcesMs. Divya Chari (Age 56)Head of Global Clinical Operations Mr. Dave GancarzChief Business & Strategy Officer?Mr. Will BlackHead of Information Technology?Dr. Betty Y. Chang Ph.D.Head of Research, Oncology & Inflammation?More ExecutivesKey CompetitorsArvinasNASDAQ:ARVNMoonLake ImmunotherapeuticsNASDAQ:MLTXIndiviorNASDAQ:INDVHUTCHMEDNASDAQ:HCMCrinetics PharmaceuticalsNASDAQ:CRNXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 919,307 shares on 3/11/2024Ownership: 1.000%Goldman Sachs Group Inc.Bought 2,210 shares on 3/1/2024Ownership: 0.028%Virtu Financial LLCBought 16,526 shares on 2/26/2024Ownership: 0.002%Virtus ETF Advisers LLCSold 15,645 shares on 2/15/2024Ownership: 0.005%Citadel Advisors LLCBought 100 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions SMMT Stock Analysis - Frequently Asked Questions How have SMMT shares performed in 2024? Summit Therapeutics' stock was trading at $2.61 on January 1st, 2024. Since then, SMMT shares have increased by 57.7% and is now trading at $4.1150. View the best growth stocks for 2024 here. Are investors shorting Summit Therapeutics? Summit Therapeutics saw a increase in short interest during the month of February. As of February 29th, there was short interest totaling 15,950,000 shares, an increase of 25.1% from the February 14th total of 12,750,000 shares. Based on an average daily trading volume, of 1,940,000 shares, the days-to-cover ratio is currently 8.2 days. Approximately 19.2% of the company's shares are sold short. View Summit Therapeutics' Short Interest. When is Summit Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our SMMT earnings forecast. How were Summit Therapeutics' earnings last quarter? Summit Therapeutics Inc. (NASDAQ:SMMT) released its quarterly earnings results on Tuesday, February, 20th. The company reported ($0.05) EPS for the quarter. The business had revenue of $0.20 million for the quarter. What ETFs hold Summit Therapeutics' stock? ETFs with the largest weight of Summit Therapeutics (NASDAQ:SMMT) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and ALPS Medical Breakthroughs ETF (SBIO).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of Summit Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include Energy Transfer (ET), Summit Therapeutics (SUMM), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), CBL & Associates Properties (CBL), SandRidge Permian Trust (PER), Cornerstone Total Return Fund (CRF), Ford Motor (F) and Martin Midstream Partners (MMLP). When did Summit Therapeutics IPO? (SMMT) raised $40 million in an initial public offering on Thursday, March 5th 2015. The company issued 3,500,000 shares at a price of $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager. Who are Summit Therapeutics' major shareholders? Summit Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.00%), Vanguard Group Inc. (1.00%), Northern Trust Corp (0.16%), Charles Schwab Investment Management Inc. (0.14%), Steward Partners Investment Advisory LLC (0.09%) and Nuveen Asset Management LLC (0.08%). Insiders that own company stock include Ankur Dhingra, Mahkam Zanganeh, Maky Zanganeh, Manmeet Singh Soni and Robert W Duggan. View institutional ownership trends. How do I buy shares of Summit Therapeutics? Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SMMT) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingBill Gates Bets on $15 Trillion BonanzaWeiss RatingsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.